Doxazosin in the current treatment of hypertension

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 4, 2008, Pages 625-633

  Wykretowicz, Andrzej ^a   Guzik, Przemyslaw ^a   Wysocki, Henryk ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Autonomic system; Blood pressure; Doxazosin; GITS; Heart failure; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LISINOPRIL; PERINDOPRIL; PLACEBO; THIAZIDE DIURETIC AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT;

ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORNING DOSAGE; MUSCLE TONE; OBESITY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; SOMNOLENCE; SYNCOPE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULAR SMOOTH MUSCLE; BLOOD PRESSURE; DRUG COMBINATION; DRUG DOSAGE FORM; DRUG EFFECT; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSAGE FORMS; DOXAZOSIN; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 40649106484     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.4.625     Document Type: Article

References (78)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-52
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536
3. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification and control in Western Europe and the United States. Arch Intern Med 2007;167(2):141-7
4. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356(9246):1955-64
5. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999;48(5):678-87
6. Grimm RH Jr. Alpha 1-antagonists in the treatment of hypertension. Hypertension 1989;13(5 Suppl):I131-6
7. Fulton B, Wagstaff A, Sorkin E. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49(2):295-320
8. Calvo C, Gil-Extremera B, Gomez-Fernández P, et al. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension. Int J Cardiol 2005;101(1):97-104
9. Os I. Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure. Int J Clin Pharmacol Ther 2006;44(3):99-106
10. Brown M, Dickerson J. Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension J Hypertens 1995;13(6):701-7
11. Troffa C, Manunta P, Dessi-Fulgheri P. Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res 1994;55(1):22-31
12. Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol 2003;41(6):866-9
13. Stafford RS, Furberg CD, Finkelstein SN, et al. Impact of clinical trial results on national trends in alpha-blocker presaibing, 1996-2002. JAMA 2004;291(1):54-62
14. Sica DA. Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich) 2005;7(12):757-62
15. Pressel SL, Davis BR, Wright JT, et al. Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials 2001;22(1):29-41
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283(15):1967-75
17. Black HR, Keck M, Meredith P, et al. Controlled-release doxazosin as combination therapy in hypertension: the GATES study J Clin Hypertens (Greenwich) 2006;8(3):159-66
18. De Alvaro F, Herndndez-Presa MA; on Behalf of the Investigators of the ASOCIA Study. Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: The ASOCIA Study. J Cardiovasc Pharmacol 2006;47(2): 271-6
19. Campo C, Segura J, Roldán C, et al. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. Blood Press Suppl 2003;12(Suppl 2):16-21
20. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906
21. Cases A. Doxazosin in a gastrointestinal therapeutic system formulation. Drugs Today (Barc) 2000;36(10):679-88
22. Steers WD, Kirby RS. Clinical ease of using doxazosin in BPH patients with and without hypertension. Prostate Cancer Prostatic Dis 2005;8(2):152-7
23. Prisant LM, Elliott WJ. Drug delivery systems for treatment of systemic hypertension. Clin Pharmacokinet 2003;42(11):931-40
24. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000;13(5 Pt 1): 468-74
25. Lemmer B, Nold G. Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension. Blood Press Monit 2003;8(3):119-25
26. Torvik D, Madsbu HP. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986;21(Suppl 1):69S-75S
27. Torvik D, Madsbu HP. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension. Am J Cardiol 1987;59(14):68G-72G
28. Tan KW, Frise SA. Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild-to-moderate hypertension. Clin Ther 1997;19(3):459-70
29. Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up. Am Heart J 1991;121(1 Pt 2):280-5
30. Smyth P, Pringle S, Jackson G, Lorimer AR. 24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo. Eur J Clin Pharmacol 1988;34(6):613-8
31. Ames RP, Kiyasu JY. Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins. J Clin Pharmacol 1989;29(2):123-7
32. Scott PJ, Hosie J, Scott MG. A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients. Eur J Clin Pharmacol 1988;34(2):119-23
33. Grimm RH Jr, Flack JM, Schoenberger JA, et al. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. Am J Hypertens 1996;9(5):445-54
34. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995;91(3):698-706
35. Ebata H, Hojo Y, Ikeda U, et al. Differential effects of an alpha 1-blocker (doxazosin) on diurnal blood pressure variation in dipper and non-dipper type hypertension. Hypertens Res 1995;18(2):125-30
36. Kamoi K, Ikarashi T. The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements. Clin Exp Hypertens 2005;27(4):369-76
37. Ishikawa J, Hoshide S, Shibasaki S, et al. The Japan Morning Surge-1 (JMS-1) study: protocol description. Hypertens Res 2006;29(3):153-9
38. Hermida RC, Calvo C, Ayala DE, et al. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int 2004;21(2):277-96
39. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42(3):239-46
40. Puller LB, Davis BR, Cutler JA, et al. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 2002;3(1):10
41. Furberg CD. A new era in hypertension research: discussing the findings of ALLHAT. Curr Control Trials Cardiovasc Med 2001;2(6):249-50
42. Krakoff LR. Comments on ALLHAT and doxazosin. Cure Control Trials Cardiovasc Med 2001;2(6):254-6
43. Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens 2000;13(8):921-6
44. Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988;116(6 Pt 2): 1826-32
45. Lindner UK, von Manteuffel GE, Stafunsky M. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988;116(6 Pt 2):1814-20
46. Searle M, Dathan R, Dean S, et al. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol 1990;39(3):299-300
47. Brown MJ, Dickerson JE. Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1991;9(6 Suppl):S362-3
48. Englert RG, Barlage U. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. Am Heart J 1991;121(1 Pt 2): 311-6
49. Donnelly R, Elliott HL, Meredith PA, et al. Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol 1992;19(4):479-86
50. Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999;34(3):375-80
51. Opie LH. Mechanism of cardiac contraction and relaxation. Chapter 19. In: Braunwald's Heart Disease, A Textbook of Cardiovascular Medicine. Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Elsevier Saunders; 2005, p. 457-89
52. Ohta Y, Tsuchihashi T, Onaka U, et al. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. Hypertens Res 2007;30(4):301-6
53. McDougall C, Brady AJ, Petrie JR. ASCOT: a tale of two treatment regimens. BMJ 2005;331(7521):859-60
54. Chang CL, Poulter NR, Chapman N, et al. The effect on blood pressure and lipid profiles of doxazosin GITS as a third-line agent in the ASCOT-BPLA trial. J Hypertens 2006;24:S3. Abstract 1A.3
55. Staessen JA, Wang JG, Birkenhäger WH. Outcome beyond blood pressure control? Eur Heart J 2003;24(6):504-14
56. Sever PS, Poulter NR, Elliott WJ, et al. Blood pressure reduction is not the only determinant of outcome. Circulation 2006;113(23):2754-72
57. Staessen JA, Thijs L, Li Y, et al. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs. Curr Opin Cardiol 2007;22(4):335-43
58. Iwamoto N, Abe-Dohmae S, Ayaori M, et al. ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade. Circ Res 2007;101(2):156-65
59. Brude IR, Drevon CA, Viken K, et al. Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies. Biochem Pharmacol 1999;58(1):183-91
60. Chait A, Gilmore M, Kawamura M. Inhibition of low density lipoprotein oxidation in vitro by the 6- and 7-hydroxy-metabolites of doxazosin, an alpha 1-adrenergic antihypertensive agent. Am J Hypertens 1994;7(2):159-67
61. Remaley AT. Old drug, new tricks: the unexpected effect of doxazosin on luigh-density lipoprotein. Circ Res 2007;101(2):116-8
62. Pessina AC, Ciccariello L, Perrone F, et al. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 2006;16(2):137-47
63. Inukai T, Inukai Y, Matsuromo R, et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res 2004;32(2):206-13
64. Derosa G, Cicero AF, D'Angelo A, et al. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin Drug Investig 2006;26(9):529-39
65. Giorda C, Appendino M. Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metabolism 1993;42(11):1440-2
66. Giorda C, Appendino M, Mason MG, et al. Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 1995;44(5):673-6
67. Courtney CH, McCance DR, Atkinson AB, et al. Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism 2003;52(9):1147-52
68. Dell'Omo G, Penno G, Pucci L, et al. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis 2005;16(1):67-73
69. Komai N, Ohishi M, Moriguchi A, et al. Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res 2002;25(1):5-10
70. Wykretowicz A, Guzik P, Krauze T, et al. Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation. Br J Clin Pharmacol 2007;64(6):792-5
71. Guzik P, Wykretowicz A, Krauze T, et al. Add-on therapy with doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system. Hypertens Res 2008;31(3):445-55
72. Veelken R, Schmieder RE. Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens 1996;9(11):139S-149S
73. Toth K, Nemes J, Czopf L, et al. Effects of doxazosin on hemorheological, hemodynamic and lipid parameters in patients with essential hypertension. Clin Hemorheol Microcirc 1999;20(1):57-61
74. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996;48(3):406-15
75. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61(1):119-26
76. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98
77. Logan YT, Belgeri MT. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Am J Geriatr Pharmacother 2005;3(2):103-14
78. Johnson TM 2nd, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007;178(5):2045-50